Recently, the MDM2 inhibitor RG7388 was developed and hit Phase III clinical trials for refractory AML, the first of the MDM2 inhibitors to reach this milestone (Montesinos et al., 2020). This evidence concerns the gene MDM2 and acute myeloid leukemia.